share_log

Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV

Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV

Trinity Biotech获得世界卫生组织的早期批准,可以开始离岸生产TrinScreen HIV和Uni-Gold HIV。
Benzinga ·  2024/12/19 00:01

Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.

专注于包括可穿戴生物传感器在内的人体诊断和糖尿病管理解决方案的商业阶段生物技术公司Trinity Biotech plc(纳斯达克股票代码:TRIB)今天宣布了其综合转型计划的重要更新,其中包括将TrinScreen HIV和Uni-Gold HIV的生产转移给成本较低的海上制造合作伙伴。三一生物科技已提前获得世界卫生组织(WHO)的批准,允许其外包供应商进行TrinScreen HIV和Uni-Gold HIV的后期生产工艺。作为其全面转型计划的一部分,该批准是公司一直在努力实现的生产转移的关键先决条件。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发